Soleno Therapeutics up on forecasting preliminary 2025 Vykat XR sales above estimates

Shares of drugmaker Soleno Therapeutics SLNO.O rise 4.1% to $44.75 premarket

Company posts preliminary 2025 net revenue related to U.S. sales of rare disease drug, Vykat XR, since Q2 launch to be in a range of $189 million to $191 million

This is above analysts' estimate of $142.96 million - data compiled by LSEG

Overall preliminary Q4 net revenue expected to be in a range of $90 million to $92 million vs estimates of $81.67 million

As of last close, stock down 0.14% in last 12 months